Junshi Bio Completes $50 Million Investment in US Partner, Coherus

Shanghai Junshi Bio completed its $50 million investment into its US partner, Coherus Biosciences. In February, the two companies announced a $1.1 billion agreement, including a $150 million upfront payment to Junshi, that gives Coherus the right to commercialize Junshi's anti-PD-1 antibody in the US and Canada . One day later, Junshi announced it would make a $50 million investment in Coherus. Junshi's Tuoyi (toripalimab) was the first China-developed anti-PD-1 antibody approved in  China . More details.... Stock Symbols: (HK: 1877; SHA: 688180) (NSDQ:CHRS) Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.